Charles Newton Acquires Shares in Novavax, Inc.
Insider Charles Newton purchased 21,270 shares of Novavax on June 18, 2026.
Key Points
- Insider Charles Newton bought 21,270 shares of Novavax, Inc. (NVAX) on June 18, 2026, with the stock trading at $9.07.
- Novavax, Inc. has a market cap of $1.48 billion and a 52-week range of $6.13 to $11.97.
- Analysts from HC Wainwright & Co. and BTIG maintain a buy rating, with price targets of $16.00 and $19.00, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Charles Newton, an insider at Novavax, Inc. (NasdaqGS: NVAX), bought 21,270 shares of the company on June 18, 2026. The transaction did not occur under a prearranged trading plan. Shares of Novavax traded at $9.07 on Wednesday.
Insider Buying and Selling at Novavax, Inc.
In addition to Charles Newton's purchase, several other insiders were active around the same time. On June 20, 2026, insiders Margaret McGlynn, David Mott, Rachel King, and Richard Douglas each bought 18,880 shares. These transactions were not planned under Rule 10b5-1 plans.
Other Institutional Activity in Novavax
Shah Capital Management increased its holdings by 286,317 shares, bringing its total to 14,845,097 shares, valued at roughly $120.8 million. BlackRock, Inc. slightly reduced its position by 57,230 shares, holding 12,844,319 shares worth about $104.6 million. State Street Corp cut its stake by 553,128 shares, ending with 8,970,518 shares valued at $73 million. D. E. Shaw & Co., Inc. significantly boosted its holdings by 1,717,060 shares, reaching 7,709,858 shares worth approximately $62.8 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions with 7,151,625 and 7,130,147 shares, respectively.
Novavax, Inc. Stock Down 2.0%
As of Wednesday, Novavax, Inc. traded at $9.07 per share. The biotechnology company, with a market cap of $1.48 billion, focuses on vaccine development. The stock's 52-week range is between $6.13 and $11.97. It has a 50-day moving average of $9.05 and a 200-day moving average of $8.47. Novavax's current ratio stands at 2.48, and its quick ratio is 2.38. The stock has a beta of 2.414, indicating higher volatility compared to the market.
$NVAX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 6, 2026, TD Cowen maintained a hold rating with a $9.00 price target on Novavax. Meanwhile, HC Wainwright & Co. reaffirmed its buy rating with a $16.00 target on February 27, 2026. BTIG reiterated its buy stance with a $19.00 target on January 20, 2026. Overall, the consensus among nine analysts is a buy, with an average target price of $14.11.
About Novavax, Inc.
Novavax, Inc. is a biotechnology firm based in Gaithersburg, Maryland. It specializes in creating vaccines to tackle serious infectious diseases. The company is known for Nuvaxovid, a COVID-19 vaccine, and the R21 Matrix-M adjuvant malaria vaccine. Novavax collaborates with major pharmaceutical firms like Sanofi and Pfizer to manufacture and distribute its vaccines. Led by CEO John Charles Jacobs, the company employs 749 people.
Bottom Line
Charles Newton's recent purchase of Novavax shares highlights ongoing insider interest in the company. Novavax remains a significant player in the biotechnology sector, focusing on vaccines for infectious diseases. With a volatile stock and varying analyst opinions, investors continue to watch the company's developments closely.
Get Novavax, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NVAX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.